5 (33.3%) CCs had a TP53 mutation. 1 ETT (16.7%) had a mutation in EGFR, and 1 PSTT (20%) had a mutation in ERBB2. No driver mutations detected in the invasive mole. This evidence concerns the gene TP53 and invasive hydatidiform mole.